1. Kura Oncology's ziftomenib shows promising Phase 2 data in newly diagnosed AML patients and is nearing FDA Priority Review for relapsed/refractory cases; 2. The pipeline expands into combination therapies with encouraging early results; 3. Strong financial position ($703M cash) and partnership with Kyowa Kirin reduce dilution risks and support commercialization.

1. PayPal's stock has declined due to Apple's introduction of competing BNPL services, but the market reaction may be overblown. 2. PayPal's recent enhancements and strong financial health suggest a potential rebound. 3. The EU ruling requiring Apple to open NFC technology to third-party providers could benefit PayPal in Europe.